Repare Therapeutics (RPTX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference overview

• Over 600 companies presented across sectors including life sciences, fintech, technology, clean tech, and mining.

• Multiple sector tracks and live panels offered, with opportunities for one-on-one meetings.

• H.C. Wainwright covers 636 companies with 24 senior analysts.

Precision oncology pipeline highlights

• Four proprietary clinical programs developed in-house, focusing on DNA damage repair and synthetic lethality.

• SNIPRx platform targets novel cancer markers, enabling precision therapies for defined patient groups.

• Strong balance sheet with $208M in cash, funding operations into H2 2026.

Key clinical programs and milestones

• Lunresertib (PKMYT1 inhibitor) targets Cyclin E1, FBXW7, PPP2R1A; first-in-class, with multiple tumor types addressed.

• Camonsertib (ATR inhibitor) focuses on ATM loss and 16 genetic alterations; active in non-small cell lung monotherapy.

• RP-1664 (PLK4 inhibitor) shows strong preclinical results in pediatric neuroblastoma; phase 1 trial underway.

• RP-3467 (Pol Theta inhibitor) IND open, clinical enrollment imminent; targets BRCA1/2, with potential in large oncology markets.